Detalhe da pesquisa
1.
A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin.
Liver Int
; 34(10): 1550-9, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24329937
2.
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
Hepatology
; 56(6): 2039-50, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22706730
3.
Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
J Clin Gastroenterol
; 47(3): 271-9, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22951527
4.
An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver.
Ann Hepatol
; 12 Suppl 2: s3-35, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23559487
5.
Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Ann Hepatol
; 11(1): 52-61, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22166561
6.
Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease.
Clin Gastroenterol Hepatol
; 9(3): 242-8, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21056689
7.
Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
Gastroenterology
; 139(6): 1972-83, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20816836
8.
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Hepatol Int
; 11(2): 188-198, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28210927
9.
A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
PLoS One
; 11(10): e0164563, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27749900